XIFAXAN® has been shown to reduce the burden on healthcare systems when used to prevent the recurrence of overt hepatic encephalopathy1-3
The use of rifaximin-α to manage patients with hepatic encephalopathy has shown reductions in hospital resource utilisation. Select a parameter to find out more.